Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (13163)	9/28/2004 2:38:24 PM
From: Michael Young	Read Replies (3) \| Respond to of 52153

How are we supposed to take AGIX's results seriously when they only evaluated 133 out of 500 trial subjects?

To: Biomaven who wrote (13163)	9/28/2004 2:57:50 PM
From: bio_kruncher	Read Replies (1) \| Respond to of 52153

re: NABI we can make educated guesses and calculate some probable p-values. 68 pts / 4 trt groups= about 17 per group. ways to get 33% are : 5/15, 6/18, 7/21 ways to get 9% are: 1/11, 2/22 (this seems odd) Chi-square pvalues range from 0.328 to 0.114 I don;t think the 2/22 is a likely outcome for placebo so i'd quess p-value is in the 0.2 - 0.3 range. OF concern would be lack of disclosure of 'quit rate' for lower dose groups and no mention of antibody results(which was the objective of the study). Interesting results but i think the study is just too small to choose a dose for smoking cessation. Larger Phase II dose ranging still needed.